AKR1C1 promotes non-small cell lung cancer proliferation via crosstalk between HIF-1α and metabolic reprogramming

Non-small cell lung cancer (NSCLC) ranks first among cancer death worldwide. Despite efficacy and safety priority, targeted therapy only benefits ∼30% patients, leading to the unchanged survival rates for whole NSCLC patients. Metabolic reprogramming occurs to offer energy and intermediates for fuel...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Lin-Lin, Lu, Pei-Hua, Yang, Wei, Hu, Yan, Zheng, Lin, Zhao, Qiong, Lin, Neng-Ming, Zhang, Wen-Zhou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034391/
https://www.ncbi.nlm.nih.gov/pubmed/35429904
http://dx.doi.org/10.1016/j.tranon.2022.101421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034391/
https://www.ncbi.nlm.nih.gov/pubmed/35429904
http://dx.doi.org/10.1016/j.tranon.2022.101421

Ejemplares similares